PROJECT

Projects

Environmental & Social Review Summary

Project Number

48629

Company Name

Luminova Pharma Alliance, Inc.

Date ESRS Disclosed

Jul 15, 2024

Country

Guatemala

Region

Latin America and the Caribbean

Last Updated Date

Sep 1, 2025

Environmental Category

B - Limited

Status

Hold

Sector

other

Industry

other

Department

Regional Industry MAS LAC & EUR

Project Description

 Luminova Pharma Group (“Luminova”, or “the Group”) is a private, family-owned pharmaceutical group founded 60 years ago and is based in Guatemala engaging in the development, manufacture, and commercialization of generics (mainly branded generics). Luminova owns two manufacturing facilities in Guatemala, with capacity for solids, semisolids, liquids, and injectables production. The company also distributes and commercializes generics in twelve countries in Central America and South American region through its own distribution function and third-party operators. The proposed investment consists of up to USD 50 million long-term financing which includes the acquisition of pharmaceutical companies located in Spain, maintenance capex, and working capital requirements. The project does not involve any new greenfield development of infrastructures.                                                        

Overview of IFC's Scope of Review

 IFC’s environmental and social (E&S) review of the project consisted of (i) a review of technical, financial, environmental and social information, (ii) a series of meetings, whereby the company representatives, including corporate environmental, health and safety, social (going forward, all together will be referred as E&S), human resources (HR), and senior management were interviewed, and (iii) physical site visit conducted by IFC’s E&S specialists in February 2024. The appraisal included the review of company’s facilities (Novoswiss plant, Helvetia plant, Headquarters office) as well as interviews of workers and third-party contractors. At the time of appraisal, the company has not completed the acquisition of Spanish company and has not initiated the acquisition of other companies in Europe. After the acquisition of the target company is completed, IFC will visit the acquired facility as part of the portfolio monitoring activities. IFC and the company mutually agree to make additions to the disclosed E&S Action Plan (ESAP), if necessary, per monitoring activity findings.                                                        

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan